JP2017524348A5 - - Google Patents

Download PDF

Info

Publication number
JP2017524348A5
JP2017524348A5 JP2016572566A JP2016572566A JP2017524348A5 JP 2017524348 A5 JP2017524348 A5 JP 2017524348A5 JP 2016572566 A JP2016572566 A JP 2016572566A JP 2016572566 A JP2016572566 A JP 2016572566A JP 2017524348 A5 JP2017524348 A5 JP 2017524348A5
Authority
JP
Japan
Prior art keywords
ptpn2
leukocytes
cell
inhibitor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016572566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2015/050318 external-priority patent/WO2015188228A1/en
Publication of JP2017524348A publication Critical patent/JP2017524348A/ja
Publication of JP2017524348A5 publication Critical patent/JP2017524348A5/ja
Pending legal-status Critical Current

Links

JP2016572566A 2014-06-10 2015-06-10 養子細胞移入のためのptpn2阻害を用いた白血球の産生方法 Pending JP2017524348A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2014902203 2014-06-10
AU2014902203A AU2014902203A0 (en) 2014-06-10 Method of producing cells for adoptive cell transfer
AU2015901171A AU2015901171A0 (en) 2015-03-31 Method of producing cells for adoptive cell transfer (2)
AU2015901171 2015-03-31
PCT/AU2015/050318 WO2015188228A1 (en) 2014-06-10 2015-06-10 Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer

Publications (2)

Publication Number Publication Date
JP2017524348A JP2017524348A (ja) 2017-08-31
JP2017524348A5 true JP2017524348A5 (Direct) 2018-06-07

Family

ID=54832624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016572566A Pending JP2017524348A (ja) 2014-06-10 2015-06-10 養子細胞移入のためのptpn2阻害を用いた白血球の産生方法

Country Status (5)

Country Link
US (2) US20170224731A1 (Direct)
EP (1) EP3154555A4 (Direct)
JP (1) JP2017524348A (Direct)
AU (1) AU2015274242A1 (Direct)
WO (1) WO2015188228A1 (Direct)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL295616A (en) 2015-07-31 2022-10-01 Us Health Adapted cells and treatment methods
EP3529359B1 (en) 2016-10-18 2023-12-13 Regents of the University of Minnesota Tumor infiltrating lymphocytes for use in therapy
WO2018148378A1 (en) * 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
CA3073755A1 (en) 2017-08-24 2019-02-28 The Royal Institution For The Advancement Of Learning/Mcgill Universit Enhancing cd8+ t cells for adoptive cell therapy by inhibiting ptpn1 (ptp1b) and ptpn2 (tc-ptp)
JP7558563B2 (ja) 2018-03-15 2024-10-01 ケーエスキュー セラピューティクス, インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
BR112020018573A2 (pt) * 2018-03-15 2020-12-29 KSQ Therapeutics, Inc. Composições e métodos de regulação gênica para imunoterapia aprimorada
JP2021518160A (ja) 2018-03-15 2021-08-02 ケーエスキュー セラピューティクス, インコーポレイテッド 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
CN112437668A (zh) * 2018-06-01 2021-03-02 莫纳什大学 通过ptp1b抑制活化细胞的方法
MA52963A (fr) 2018-06-21 2021-04-28 Abbvie Inc Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation
US20220081691A1 (en) * 2018-08-07 2022-03-17 Dana-Farber Cancer Institute, Inc Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
MX2021009357A (es) * 2019-02-04 2021-11-17 Ksq Therapeutics Inc Dianas de genes de combinacion para mejorar la inmunoterapia.
MX2021010544A (es) 2019-03-14 2021-10-01 Calico Life Sciences Llc Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos.
US12188045B2 (en) 2019-06-07 2025-01-07 KSQ Therapeutics, Inc. Guide RNA combinations and methods of use
AU2020392094A1 (en) * 2019-11-25 2022-06-23 KSQ Therapeutics, Inc. Methods for activation and expansion of tumor infiltrating lymphocytes
EP4069260A4 (en) * 2019-12-04 2024-06-12 Monash University METHODS OF ACTIVATING CYTOTOXIC LEUKOCYTES USING PTP1B AND PTPN2 INHIBITORS
AU2020401376A1 (en) * 2019-12-12 2022-06-30 Kumquat Biosciences Inc. Compositions and methods for potentiating immune activity
CN113827727B (zh) * 2020-06-24 2025-04-29 上海交通大学医学院附属瑞金医院 Ptpn2抑制剂在kras突变肿瘤中的应用
PE20241173A1 (es) 2021-10-14 2024-05-28 Arsenal Biosciences Inc Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica
IL322949A (en) 2023-03-03 2025-10-01 Arsenal Biosciences Inc Systems targeting PSMA and CA9
TW202500126A (zh) 2023-05-24 2025-01-01 美商金橘生物科技公司 雜環化合物及其用途
WO2025075947A1 (en) * 2023-10-06 2025-04-10 Purdue Research Foundation Selective tc-ptp degraders for cancer immunotherapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008043181A1 (en) * 2006-10-12 2008-04-17 Mcgill University Augmenting stem cell populations by modulating t-cell protein tyrosine phosphatase (tc-ptp)
US9217012B2 (en) * 2009-04-08 2015-12-22 Indiana University Research And Technology Corporation Inhibitors of protein tyrosine phosphatases
WO2014039513A2 (en) * 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
EP2904106A4 (en) * 2012-10-01 2016-05-11 Univ Pennsylvania COMPOSITIONS AND METHOD FOR TARGETING CURRIC ACIDS FOR THE TREATMENT OF CANCER
WO2014066137A1 (en) * 2012-10-22 2014-05-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for enhancing cancer immunotherapy
AU2014266833B2 (en) * 2013-05-13 2020-07-02 Cellectis Methods for engineering highly active T cell for immunotherapy
MX2015016963A (es) * 2013-06-10 2016-08-08 Dana Farber Cancer Inst Inc Metodos y composiciones para reducir la inmunosupresion por celulas de tumor.
CN106471004A (zh) * 2014-02-28 2017-03-01 麦吉尔大学学术发展皇家学院 作为用于免疫疗法的apc活化剂的tc‑ptp抑制剂
EP3116902B1 (en) * 2014-03-11 2020-01-01 Cellectis Method for generating t-cells compatible for allogenic transplantation

Similar Documents

Publication Publication Date Title
JP2017524348A5 (Direct)
JP2023055884A5 (Direct)
US11141471B2 (en) Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells
CN110944675A (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP2019509029A5 (Direct)
US20190106679A1 (en) Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
US20190167720A1 (en) Gene editing for immunological destruction of neoplasia
HRP20230150T1 (hr) Konstrukcija kimernog antigenskog receptora koji cilja cd20 antigen i identifikacija aktivnosti njegovih inženjerskih t-stanica
JP2019506175A5 (Direct)
RU2017139121A (ru) Композиции для модулирования экспрессии c9orf72
JP2019527055A5 (Direct)
WO2017075478A2 (en) Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
JP2013530689A5 (Direct)
US12473553B2 (en) RNA nanostructures and methods of making and using RNA nanostructures
JP2017508744A5 (Direct)
JP2013521789A5 (Direct)
JP2019512020A5 (Direct)
WO2020214650A1 (en) Methods and compositions for modulating the immune system
JP2017536826A5 (Direct)
JP2013507934A5 (Direct)
JP2015524413A5 (Direct)
RU2014121304A (ru) Ингибирование экспрессии вирусных генов
Kher et al. Antisense oligonucleotides and RNA interference
JP2019505210A5 (Direct)
JP2010270119A5 (Direct)